Reslizumab

Anaphylaxis

• Anaphylaxis occurred with CINQAIR infusion in 0.3% of patients in placeb-controlled studies
• Patients should be observed for an appropriate period of time after CINQAIR infusion; healthcare should be prepared to manage anaphylaxis that can be life-threatening
• Discontinue CINQAIR immediately if the patient experiences anaphylaxis

Patient Counseling Information

• CINQAIR

Package Inserts

Reslizumab